Broader studies have shown that ASNS’s impact on cancer progression and therapy response is tightly interwoven with other metabolic vulnerabilities, including glutamine, arginine, and polyamine dependency, and the tightly regulated crosstalk between mTOR, NOTCH, and GCN2 signaling pathways. Here, EIF2AK4 is linked to cancer.